Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment

Rita Paniccia, Emilia Antonucci, Anna Maria Gori, Rossella Marcucci, Serena Poli, Eloisa Romano, Serafina Valente, Cristina Giglioli, Sandra Fedi, Gian Franco Gensini, Rosanna Abbate, Domenico Prisco

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Patients with coronary artery disease (CAD) receiving aspirin therapy with a residual platelet reactivity (RPR) may be at increased risk of ischemic vascular events. Point-of-care (POC) methods PFA-100 (Dade-Behring, Marburg, Germany) and VerifyNow (Accumetrics, San Diego, CA) assays have been suggested as rapid tools to evaluate RPR. We compared PFA-100 closure times by collagen/epinephrine and VerifyNow Aspirin assays with light transmission aggregation (LTA) induced by 1 mmol/L of arachidonic acid in 484 patients with CAD undergoing percutaneous coronary intervention and receiving dual antiplatelet therapy. RPR was detected in 30.0% of patients by LTA, in 32.4% by PFA-100, and in 14.3% by VerifyNow. Significant correlations were found among 3 methods (all P <.0001). In relation to the presence or absence of RPR by LTA and PFA-100, by LTA and VerifyNow, and by PFA-100 and VerifyNow, samples were significantly concordant (all P <.0001). Assuming LTA as the reference method, PFA-100 and VerifyNow showed sensitivity of 62.1% and 39.3% and specificity of 80.2% and 96.4%, respectively. The cutoff values for POC methods need to be defined for clinical use.

Original languageEnglish
Pages (from-to)143-149
Number of pages7
JournalAmerican Journal of Clinical Pathology
Volume128
Issue number1
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Aspirin
Myocardial Ischemia
Blood Platelets
Light
Point-of-Care Systems
Coronary Artery Disease
Therapeutics
Percutaneous Coronary Intervention
Arachidonic Acid
Epinephrine
Germany
Blood Vessels
Collagen

Keywords

  • Aggregation
  • Aspirin
  • Platelet
  • Point-of-care testing

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. / Paniccia, Rita; Antonucci, Emilia; Gori, Anna Maria; Marcucci, Rossella; Poli, Serena; Romano, Eloisa; Valente, Serafina; Giglioli, Cristina; Fedi, Sandra; Gensini, Gian Franco; Abbate, Rosanna; Prisco, Domenico.

In: American Journal of Clinical Pathology, Vol. 128, No. 1, 07.2007, p. 143-149.

Research output: Contribution to journalArticle

Paniccia, R, Antonucci, E, Gori, AM, Marcucci, R, Poli, S, Romano, E, Valente, S, Giglioli, C, Fedi, S, Gensini, GF, Abbate, R & Prisco, D 2007, 'Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment', American Journal of Clinical Pathology, vol. 128, no. 1, pp. 143-149. https://doi.org/10.1309/0G1PEJ00J8KP8357
Paniccia, Rita ; Antonucci, Emilia ; Gori, Anna Maria ; Marcucci, Rossella ; Poli, Serena ; Romano, Eloisa ; Valente, Serafina ; Giglioli, Cristina ; Fedi, Sandra ; Gensini, Gian Franco ; Abbate, Rosanna ; Prisco, Domenico. / Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. In: American Journal of Clinical Pathology. 2007 ; Vol. 128, No. 1. pp. 143-149.
@article{4f31174c050141ce9aca4e081a61a403,
title = "Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment",
abstract = "Patients with coronary artery disease (CAD) receiving aspirin therapy with a residual platelet reactivity (RPR) may be at increased risk of ischemic vascular events. Point-of-care (POC) methods PFA-100 (Dade-Behring, Marburg, Germany) and VerifyNow (Accumetrics, San Diego, CA) assays have been suggested as rapid tools to evaluate RPR. We compared PFA-100 closure times by collagen/epinephrine and VerifyNow Aspirin assays with light transmission aggregation (LTA) induced by 1 mmol/L of arachidonic acid in 484 patients with CAD undergoing percutaneous coronary intervention and receiving dual antiplatelet therapy. RPR was detected in 30.0{\%} of patients by LTA, in 32.4{\%} by PFA-100, and in 14.3{\%} by VerifyNow. Significant correlations were found among 3 methods (all P <.0001). In relation to the presence or absence of RPR by LTA and PFA-100, by LTA and VerifyNow, and by PFA-100 and VerifyNow, samples were significantly concordant (all P <.0001). Assuming LTA as the reference method, PFA-100 and VerifyNow showed sensitivity of 62.1{\%} and 39.3{\%} and specificity of 80.2{\%} and 96.4{\%}, respectively. The cutoff values for POC methods need to be defined for clinical use.",
keywords = "Aggregation, Aspirin, Platelet, Point-of-care testing",
author = "Rita Paniccia and Emilia Antonucci and Gori, {Anna Maria} and Rossella Marcucci and Serena Poli and Eloisa Romano and Serafina Valente and Cristina Giglioli and Sandra Fedi and Gensini, {Gian Franco} and Rosanna Abbate and Domenico Prisco",
year = "2007",
month = "7",
doi = "10.1309/0G1PEJ00J8KP8357",
language = "English",
volume = "128",
pages = "143--149",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment

AU - Paniccia, Rita

AU - Antonucci, Emilia

AU - Gori, Anna Maria

AU - Marcucci, Rossella

AU - Poli, Serena

AU - Romano, Eloisa

AU - Valente, Serafina

AU - Giglioli, Cristina

AU - Fedi, Sandra

AU - Gensini, Gian Franco

AU - Abbate, Rosanna

AU - Prisco, Domenico

PY - 2007/7

Y1 - 2007/7

N2 - Patients with coronary artery disease (CAD) receiving aspirin therapy with a residual platelet reactivity (RPR) may be at increased risk of ischemic vascular events. Point-of-care (POC) methods PFA-100 (Dade-Behring, Marburg, Germany) and VerifyNow (Accumetrics, San Diego, CA) assays have been suggested as rapid tools to evaluate RPR. We compared PFA-100 closure times by collagen/epinephrine and VerifyNow Aspirin assays with light transmission aggregation (LTA) induced by 1 mmol/L of arachidonic acid in 484 patients with CAD undergoing percutaneous coronary intervention and receiving dual antiplatelet therapy. RPR was detected in 30.0% of patients by LTA, in 32.4% by PFA-100, and in 14.3% by VerifyNow. Significant correlations were found among 3 methods (all P <.0001). In relation to the presence or absence of RPR by LTA and PFA-100, by LTA and VerifyNow, and by PFA-100 and VerifyNow, samples were significantly concordant (all P <.0001). Assuming LTA as the reference method, PFA-100 and VerifyNow showed sensitivity of 62.1% and 39.3% and specificity of 80.2% and 96.4%, respectively. The cutoff values for POC methods need to be defined for clinical use.

AB - Patients with coronary artery disease (CAD) receiving aspirin therapy with a residual platelet reactivity (RPR) may be at increased risk of ischemic vascular events. Point-of-care (POC) methods PFA-100 (Dade-Behring, Marburg, Germany) and VerifyNow (Accumetrics, San Diego, CA) assays have been suggested as rapid tools to evaluate RPR. We compared PFA-100 closure times by collagen/epinephrine and VerifyNow Aspirin assays with light transmission aggregation (LTA) induced by 1 mmol/L of arachidonic acid in 484 patients with CAD undergoing percutaneous coronary intervention and receiving dual antiplatelet therapy. RPR was detected in 30.0% of patients by LTA, in 32.4% by PFA-100, and in 14.3% by VerifyNow. Significant correlations were found among 3 methods (all P <.0001). In relation to the presence or absence of RPR by LTA and PFA-100, by LTA and VerifyNow, and by PFA-100 and VerifyNow, samples were significantly concordant (all P <.0001). Assuming LTA as the reference method, PFA-100 and VerifyNow showed sensitivity of 62.1% and 39.3% and specificity of 80.2% and 96.4%, respectively. The cutoff values for POC methods need to be defined for clinical use.

KW - Aggregation

KW - Aspirin

KW - Platelet

KW - Point-of-care testing

UR - http://www.scopus.com/inward/record.url?scp=34547104001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547104001&partnerID=8YFLogxK

U2 - 10.1309/0G1PEJ00J8KP8357

DO - 10.1309/0G1PEJ00J8KP8357

M3 - Article

C2 - 17580282

AN - SCOPUS:34547104001

VL - 128

SP - 143

EP - 149

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 1

ER -